|
|
|
|
|||||
|
|
|
ROCKAWAY, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The conference will take place in New York on Thursday, November 20, 2025 at The Westin NY Grand Central Hotel.
Management will host one-on-one meetings throughout the day.
Investors who wish to request a meeting should contact their sales representative at Canaccord Genuity or reach out to electroCore Investor Relations at ecor@fnkir.com.
About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products to treat chronic pain syndromes through non-invasive neuromodulation technology are gammaCore non-invasive vagus nerve stimulation, or nVNS, and the Quell® Fibromyalgia. Additionally, the Company commercializes its handheld and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Contact
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
| 5 hours | |
| Apr-01 | |
| Mar-31 | |
| Mar-30 | |
| Mar-26 | |
| Mar-23 | |
| Mar-19 | |
| Mar-19 | |
| Mar-18 | |
| Mar-10 | |
| Mar-09 | |
| Mar-05 | |
| Mar-04 | |
| Mar-04 | |
| Feb-27 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite